3
Participants
Start Date
April 30, 2009
Primary Completion Date
February 28, 2010
Study Completion Date
February 28, 2010
Rituximab
Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
Plasma exchange
Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
Corticosteroids
1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
New York-Presbyterian Hospital/Weill Cornell Medical Center, New York
Children's Hospital of Pittsburgh, Pittsburgh
University of Pittsburgh Presbyterian and Shadyside Hospital, Pittsburgh
University of Pennsylvania, Philadelphia
University of Maryland Medical Center, Baltimore
Johns Hopkins Hospital, Baltimore
University of North Carolina Hospitals, Chapel Hill
Duke University Medical Center, Durham
Emory University, Atlanta
University of Alabama, Birmingham, Birmingham
University Hospital Cleveland, Cleveland
University of Iowa, Iowa City
Froedtert Memorial Lutheran Hospital, Milwaukee
University of Wisconsin at Madison, Madison
Gunderson Clinic, LTD, La Crosse
Tulane University Health Sciences Center, New Orleans
University of Oklahoma Health Sciences Center, Oklahoma City
Integris Baptist Medical Center, Oklahoma City
Puget Sound Blood Center, Seattle
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Brigham and Women's Hospital, Boston
Children's Hospital Boston, Boston
Lead Sponsor
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Genentech, Inc.
INDUSTRY
Carelon Research
OTHER